Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 345 followers
Latest posts
Last updated 3 days ago
Reminder: Invitation to Roche’s First Quarter Sales 2025 Presentation
3 days ago
Roche will publish its Sales Results for the 1st Quarter 2025 prior...
Invitation to Roche’s Diagnostics Day 2025
5 days ago
The Roche Investor Relations team would like to invite you to the...
European Commission approves Roche’s Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy
6 days ago
Approval based on Phase III STARGLO study where Columvi in combination with...
Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025
17 days ago
New trontinemab data continue to support rapid and deep, dose-dependent reduction of...
Roche provides update on Phase III OCREVUS high dose study in people with relapsing multiple sclerosis
17 days ago
MUSETTE trial was designed to determine whether a higher dose of the...
Roche’s Greenhouse Gas Reduction Targets Validated by the Science Based Targets initiative (SBTi)
18 days ago
Roche has received the validation of its near-term and long-term greenhouse gas...
Reminder: Invitation to Roche’s Virtual Neurology Investor Event
23 days ago
We are pleased to invite investors and analysts to participate in our...
Roche Annual General Meeting 2025
26 days ago
Shareholders approved all proposals of the Board of Directors Severin Schwan was...
Invitation to Roche’s First Quarter Sales 2025 Presentation
27 days ago
Roche will publish its Sales Results for the 1st Quarter 2025 prior...
Roche to share latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association (MDA) 2025 conference
about 1 month ago
New Evrysdi five-year data from the SUNFISH study showed continued stabilisation of...
Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight and obesity
about 1 month ago
Agreement allows for a range of potentially best-in-class therapy options as monotherapy...
FDA accepts supplemental Biologics License Application for Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis
about 2 months ago
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody in a randomised phase III...